Tanezumab, identified by the catalog designation 880266-57-9, represents a targeted antibody reagent demonstrating significant potential in managing chronic osteoarthritis pain. This modified antibody uniquely targets nerve growth factor , blocking its activity and thereby lessening pain within affected locations. The ongoing data surrounding 880266-57-9 highlights its ability to offer significant pain alleviation while possibly mitigating the need for opioid analgesics. Further investigation are diligently underway to completely evaluate its lasting well-being and effectiveness .
Grasping Tanezumab's Role in Pain Alleviation: An Body's Defense Outlook
Tanezumab, a novel medicinal approach, offers a specific pathway in long-term pain alleviation. As a engineered antibody, it selectively targets and inhibits nerve growth factor (NGF), a critical molecule engaged in sensory discomfort signaling. website Unlike conventional narcotic medications, tanezumab’s protein mechanism allows for a focused targeted action, arguably reducing the risk of some frequent side consequences linked with generalized pain alleviation. However, its protein nature necessitates a careful assessment of potential immune effects and sustained consequences when utilized within a full pain management strategy.
Tanezumab Solution (880266-57-9): Purity , Purity & Uses
The Tanezumab Solution with the identifier 880266-57-9 is a critical component in various scientific applications, particularly concerning joint pain treatment development. Achieving a high degree of purity is paramount; therefore, rigorous analysis protocols are employed to guarantee its suitability for specific use. Our creation procedure focuses on maximizing refinement, employing sophisticated purification techniques to remove impurities . Typical specifications include a >95% purity level as determined by Chromatography and comprehensive verification for molecular integrity. The primary uses revolve around its role as a research tool for investigating the mechanisms of arthritis progression and developing novel therapeutic interventions .
- Research Investigations
- Drug Development
- Mechanism Studies
A Science Regarding Tanezumab:
Tanezumab, identified with the chemical identifier 880266-57-9, represents a novel medicinal immunoglobulin targeting sensory factor substance receptor (NGF). This process of effect revolves upon precisely attaching to NGF, thereby inhibiting its activity and later communication transduction. Scientists have revealed that this molecular compound provides promise for reducing persistent suffering, particularly in illnesses like arthritic conditions and chronic back pain. Additional investigations are underway to fully characterize its effectiveness and safety profile.
New Developments in The Investigation: Focusing on the Its Compound
Ongoing research surrounding tanezumab, a promising therapeutic compound, are increasingly focused on understanding the role of the identified reagent, 880266-57-9. This discovery and detailed assessment of such molecular entity suggests vital for optimizing the drug's effectiveness and reducing possible adverse reactions. Early findings reveal that 880266-57-9 contributes a important part in the therapy's mechanism of action. Further investigations will be needed to fully clarify this reagent's effect.
Tanezumab Antibody (880266-57-9): Production, Characteristics, and Potential
The production process of tanezumab, an humanized monoclonal antibody (identified by CAS number 880266-57-9), typically involves mammalian cell culture, often utilizing Chinese hamster ovary cells for high yield. Its primary characteristic is its ability to selectively target and degrade cathepsin-K, an enzyme crucial for bone resorption. This binding mechanism results in a significant reduction in osteoclast activity. The molecule exhibits a defined molecular weight and specific amino acid sequence, allowing for detailed characterization through techniques such as mass spectrometry and protein sequencing. Consequently, tanezumab’s potential lies in treating conditions characterized by excessive bone loss, like osteoarthritis and metastatic bone disease, although clinical development has been complex due to adverse event profiles and ongoing evaluation.}